Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed.

1. Low cholesterol? Don't brag yet ... hypocholesterolemia blunts HAART effectiveness: a longitudinal study.Journal of the International AIDS Society · 2010
   Trial
2. Preventive HIV Vaccines-Leveraging on Lessons from the Past to Pave the Way Forward.Vaccines · 2021
   Review
3. Major Scientific Hurdles in HIV Vaccine Development: Historical Perspective and Future Directions.Frontiers in immunology · 2020
   Review
4. Frontiers in immunology · 2018
   Article
5. Generation of antigen-specific immunity following systemic immunization with DNA vaccine encoding CCL25 chemokine immunoadjuvant.Human vaccines & immunotherapeutics · 2012
   Article
6. Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs.Journal of virology · 2011
   Article
7. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations.The Journal of general virology · 2011
   Article
8. Immune modulation through 4-1BB enhances SIV vaccine protection in non-human primates against SIVmac251 challenge.PloS one · 2011
   Article
9. Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques.Vaccine · 2010
   Article
10. Plasmids encoding the mucosal chemokines CCL27 and CCL28 are effective adjuvants in eliciting antigen-specific immunity in vivo.Gene therapy · 2010
    Article
11. Lentiviral vector-based prime/boost vaccination against AIDS: pilot study shows protection against Simian immunodeficiency virus SIVmac251 challenge in macaques.Journal of virology · 2009
    Article
12. Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo.Human gene therapy · 2009
    Article
13. Prospects for control of emerging infectious diseases with plasmid DNA vaccines.Journal of immune based therapies and vaccines · 2009
    Article
14. Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity.Blood · 2009
    Article
15. A recombinant DNA and vaccinia virus prime-boost regimen induces potent long-term T-cell responses to HCV in BALB/c mice.Vaccine · 2009
    Article
16. CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals.Vaccine · 2008
    Article
17. DNA vaccines: developing new strategies to enhance immune responses.Immunologic research · 2008
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as